The Elecsys Total PSA (Prostate-Specific Antigen) is a diagnostic test offered by Roche Diagnostics. It is used for the quantitative measurement of total PSA in human serum or plasma. PSA is a protein produced by the cells of the prostate gland, and its levels can be elevated in various prostate conditions, including prostate cancer.
The Elecsys Total PSA test utilizes an electrochemiluminescence immunoassay (ECLIA) technology. It is performed on Roche Elecsys immunoassay analyzers, which are automated systems used in clinical laboratories.
The measurement of total PSA is commonly used in the screening, diagnosis, and monitoring of prostate cancer. However, it’s important to note that elevated PSA levels can also occur in non-cancerous conditions, such as benign prostatic hyperplasia (BPH) or prostatitis.
The reference ranges for total PSA levels may vary depending on factors such as age and individual patient characteristics. It’s important to interpret the results in conjunction with other clinical information and follow the guidelines established by healthcare professionals.
It’s worth noting that the information provided is based on general knowledge up until September 2021, and there may have been updates or new versions of the product since then. For the most accurate and up-to-date information, it’s recommended to refer to the product documentation or contact Roche Diagnostics directly.
